LogicMark, Inc. to Adjourn Special Meeting of Stockholders
LogicMark, Inc. (NASDAQ: LGMK) has adjourned its Special Meeting of Stockholders from March 2, 2023, to March 7, 2023. This decision allows shareholders additional time to vote on proposals in the Proxy Statement filed on January 31, 2023. The company emphasizes the importance of each shareholder's vote, regardless of share ownership. Stockholders can vote online using their proxy control number. Those who voted against prior proposals are encouraged to reconsider their votes. Assistance is available from the proxy solicitor, Laurel Hill Advisory Group.
- Shareholders are provided additional time to vote on important proposals.
- Company emphasizes the significance of each stockholder's vote, fostering engagement.
- Adjournment may indicate potential lack of shareholder support for proposals.
LOUISVILLE, Ky., March 01, 2023 (GLOBE NEWSWIRE) -- LogicMark, Inc. (NASDAQ: LGMK) (the “Company”) today announced that the Company plans to adjourn the Special Meeting of Stockholders, which had been scheduled for Thursday, March 2, 2023 at 1:00 p.m. (Eastern Time), to Tuesday, March 7, 2023 at 1:00 p.m. (Eastern Time), to be held at the offices of Sullivan & Worcester LLP at 1633 Broadway, 32nd Floor, New York, NY 10019. The Company will announce such adjournment at the currently scheduled Special Meeting.
The Company is adjourning the Special Meeting to allow its stockholders additional time to vote on the proposals that are described in the Proxy Statement on Schedule 14A, filed with the U.S. Securities and Exchange Commission on January 31, 2023, as amended on February 2, 2023, and mailed to stockholders on or about February 1, 2023 (the “Proxy Statement”).
Each stockholder’s vote matters and is important no matter how many shares that they own. The Company requests that its stockholders please take the time to read and respond to the Company’s proxy materials that were previously provided to them and vote promptly. Voting on the Internet will require that the Company’s stockholders have their proxy control number available. That number is either printed on the voting instruction form, if stockholders received a physical copy of the proxy materials, or accessible through the voting portal, if the proxy materials were electronically delivered. Stockholders who have sold their shares but were a holder of record at the close of business on January 25, 2023, the record date for the Special Meeting, remain entitled to vote. The Company encourages its stockholders who have already voted against any of the proposals in the Proxy Statement to reconsider how they voted. In particular, the Board encourages stockholders to vote “FOR” each of the proposals described in the Proxy Statement.
Stockholders who need assistance in submitting their proxy or voting their shares should call the Company’s proxy solicitor, Laurel Hill Advisory Group, at 888-742-1305.
About LogicMark, Inc.
LogicMark, Inc. (Nasdaq: LGMK) provides personal emergency response systems (PERS), health communications devices and technologies to create a Connected Care Platform. The Company’s devices give people the ability to receive care at home and confidence to age in place. LogicMark revolutionized the PERS industry by incorporating two-way voice communication technology directly into its medical alert pendant and providing this life-saving technology at a price point everyday consumers can afford. The Company’s PERS technologies are sold through the United States Veterans Health Administration and dealers/distributors. LogicMark has been awarded a contract by the U.S. General Services Administration that enables the Company to distribute its products to federal, state, and local governments.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the Special Meeting, the proposals in the Proxy Statement and the successful execution of the Company’s business strategy. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the Company’s ability to implement its long range business plan for various applications of its technology; the Company’s ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company’s technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company’s reports filed with the SEC.
Investor Relations Contact:
CORE IR
Investor@logicmark.com
516 222 2560
Media:
Jules Abraham
julesa@coreir.com
Note: Notwithstanding the foregoing or anything to the contrary contained herein, due to ongoing public health concerns regarding the COVID-19 pandemic and for the health and well-being of our stockholders, directors, management and associates, the Company is planning for the possibility that there may be limitations on attending the Special Meeting in person, or the Company may decide to hold the Special Meeting on a different date, at a different location or by means of remote communication (i.e., a “virtual meeting”).
FAQ
Why was the LogicMark Special Meeting adjourned to March 7, 2023?
What is the significance of the Proxy Statement for LogicMark shareholders?
How can LogicMark shareholders vote on the proposals?
What should shareholders do if they previously voted against the proposals?